Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 297 pages

Showing 251 - 297


lung cancer

Adding Ziv-Aflibercept to Topotecan Improves Progression-Free Survival but Increases Toxicity in Platinum-Treated Small Cell Lung Cancer

The phase II Southwest Oncology Group (SWOG) S0802 trial reported in the Journal of Clinical Oncology by Allen et al showed that adding ziv-aflibercept (Zaltrap) to topotecan improved 3-month progression-free survival, but increased toxicity and had no effect on overall survival, in patients...

lung cancer

Propensity-Matched Analysis Shows Similar Outcomes for Segmentectomy vs Lobectomy in Stage I NSCLC

Recent retrospective, single-institution analyses have suggested that anatomic segmentectomy results in freedom from recurrence and survival rates similar to those achieved by lobectomy in lung cancer. In a large propensity-matched analysis reported in the Journal of Clinical Oncology, Landreneau...

lung cancer

No Improvement in Local Recurrence With Brachytherapy After Sublobar Resection in Patients With High-Risk Stage I NSCLC

In the phase III American College of Surgeons Oncology Group (ACOSOG) Z4032/Alliance trial reported in the Journal of Clinical Oncology, Fernando et al found that adjuvant brachytherapy did not improve risk for local recurrence after sublobar resection in patients with high-risk stage I operable...

lung cancer

Phase III Trial of Adding Figitumumab to Chemotherapy in Advanced Nonadenocarcinoma NSCLC Stopped Early for Futility and Increased Harm

In the first phase III trial assessing the combination of an insulin-like growth factor 1 receptor (IGF-1R) inhibitor with chemotherapy as first-line treatment for advanced nonadenocarcinoma non–small cell lung cancer (NSCLC), the addition of the fully human immunoglobulin G2 monoclonal...

lung cancer
issues in oncology

NLST Analysis: Lung Screening–Detected Abnormalities Other Than Cancer Result in Smoking Cessation

In a study reported in the Journal of the National Cancer Institute, Tammemägi et al assessed smoking cessation rates among participants undergoing chest x-ray or computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). Among patients without a subsequent ...

lung cancer

No Progression-Free or Overall Survival Benefit With Second- or Third-Line Erlotinib vs Docetaxel in EGFR-Unselected Japanese NSCLC Patients

In a Japanese phase III trial (DELTA) reported in the Journal of Clinical Oncology, Kawaguchi et al found that erlotinib (Tarceva) was associated with no progression-free survival or overall survival advantage as second- or third-line therapy in EGFR-unselected patients with non–small cell...

lung cancer

Proteomic Signature for EGFR Inhibitor Therapy Predicts Survival Benefit of Second-Line Chemotherapy vs Erlotinib in NSCLC

There are conflicting data on whether epidermal growth factor receptor (EGFR) inhibitor therapy is beneficial in second-line treatment of lung cancer patients with unknown or wild-type EGFR status. In a phase III trial (PROSE) reported in The Lancet Oncology, Gregorc et al assessed the predictive...

lung cancer

IASLC/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma Has Predictive Value for Recurrence and Survival

In a study reported in the Journal of Clinical Oncology, Hung et al assessed the ability of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification system to predict disease recurrence and...

lung cancer
supportive care

Modafinil Not Better Than Placebo for Fatigue in Lung Cancer Patients

In a trial reported in the Journal of Clinical Oncology, Spathis et al found that that the central nervous system (CNS) stimulant modafinil had no effect on fatigue compared with placebo in patients with advanced non–small cell lung cancer (NSCLC). Fatigue improved in both groups during the...

lung cancer

First-Generation EGFR Tyrosine Kinase Inhibitors Associated With Poorer Progression-Free Survival vs Conventional Chemotherapy in EGFR Wild-Type NSCLC

Activating EGFR mutations are found in approximately 10% of Western patients and 50% of Asian patients with non–small cell lung cancer (NSCLC), and EGFR tyrosine kinase inhibitors are recommended for use in first-line treatment in this setting. Both tyrosine kinase inhibitors and cytotoxic...

lung cancer
issues in oncology

‘Too Much and Too Little Care’ in Pulmonary Nodule Evaluation

Pulmonary nodules are common and many more will be found with implementation of lung cancer screening. In a retrospective cohort study reported in JAMA Internal Medicine, Wiener et al found that patients with pulmonary nodules were at high risk of both underevaluation and overevaluation for cancer, ...

breast cancer
lung cancer
issues in oncology

Breast Cancer Risk Variant Associated With Increased Lung Cancer Risk in Women

In a study reported in the Journal of the National Cancer Institute, Park et al examined single nucleotide polymorphisms (SNPs) associated with other cancers for potential associations with lung cancer. They found that the breast cancer SNP LSP1 rs3817198 was associated with significant risk of...

issues in oncology
lung cancer

MET Immunohistochemistry Expression Is Best Predictor of Benefit From Addition of Onartuzumab to Erlotinib in Advanced NSCLC

A recent phase II study showed progression-free survival and overall survival benefits with the addition of onartuzumab (an antibody directed against MET, a receptor kinase that binds hepatocyte growth factor [HGF]) to erlotinib (Tarceva) in the subset of patients with advanced non–small cell ...

issues in oncology
lung cancer

Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts

In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair...

lung cancer
issues in oncology

Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment

Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...

lung cancer

Trends in Phase III Trials in Advanced NSCLC: Decline in Use of Overall Survival as Primary Endpoint, More ‘Positive’ Outcomes

In a study published in the Journal of Clinical Oncology, Sacher et al identified trends in reporting of phase III trials in advanced non–small cell lung cancer (NSCLC) that include reduced use of overall survival as the primary endpoint and an increase in claims of positive outcomes despite...

lung cancer

Meta-Analysis Shows Survival Benefit of Preoperative Chemotherapy in NSCLC

In a systematic review and individual patient meta-analysis reported in The Lancet, the NSCLC Meta-analysis Collaborative Group found that neoadjuvant therapy for non–small cell lung cancer (NSCLC) was associated with a significant 13% reduction in risk of death. Significant benefits in...

lung cancer

Minimal Pleural Effusion Predicts Poorer Survival in Non–Small Cell Lung Cancer

In a study reported in the Journal of Clinical Oncology, Ryu et al found that presence of minimal pleural effusion is associated with worsened survival in patients with non–small cell lung cancer (NSCLC) compared with no effusion, particularly among patients with early-stage disease. Study...

lung cancer

Afatinib Improves Progression-Free Survival vs Cisplatin/Gemcitabine in First-Line Treatment of Asian Patients With Advanced EGFR-Mutant NSCLC

Afatinib (Gilotrif) improves progression-free survival compared with pemetrexed (Alimta)/cisplatin in first-line treatment of patients with EGFR mutation–positive advanced non–small cell lung cancer (NSCLC). In the phase III LUX-Lung 6 trial reported in The Lancet Oncology, Wu ...

lung cancer

Addition of Nintedanib to Docetaxel Improves Progression-Free Survival as Second-Line Treatment in NSCLC

In a phase III trial (LUME-Lung 1) reported in The Lancet Oncology, Reck et al assessed the addition of nintedanib to docetaxel in second-line treatment of non–small cell lung cancer (NSCLC). The combination significantly improved progression-free survival in all patients and improved overall ...

issues in oncology
lung cancer
issues in oncology

MicroRNA Test Reduces False-Positive CT Screening Rate for Lung Cancer

Although recent data indicate that low-dose computed tomography (CT) reduces lung cancer mortality in high-risk patients, high false-positive rates, costs, and the potential for harm point out the need for biomarkers that can improve risk assessment. In a study reported in the Journal of Clinical...

lung cancer

Study Evaluates Risk of Depression by Race and Sex Among Patients With Newly Diagnosed Lung Cancer

In a study reported in the Journal of Clinical Oncology, Traeger et al evaluated risk of depression symptoms and psychosocial service use by race and sex among patients with newly diagnosed lung cancer. The investigators found that black men have the highest prevalence of depressive symptoms, white ...

lung cancer
issues in oncology

Low-Dose CT Screening May Result in Overdiagnosis of Lung Cancer

In a study reported in JAMA Internal Medicine, Patz et al of the NLST Overdiagnosis Manuscript Writing Team estimated the magnitude of overdiagnosis using low-dose computed tomography (CT) screening for lung cancer in the National Lung Screening Trial (NLST). They estimated that more than 18% of...

lung cancer

No Survival Benefit for Tecemotide After Chemoradiotherapy in Stage III NSCLC

In the phase III START trial reported in The Lancet Oncology, Butts et al assessed whether maintenance treatment with the MUC1 antigen–specific immunotherapy tecemotide could prolong overall survival in patients with unresectable stage III non–small cell lung cancer (NSCLC) who had...

issues in oncology
lung cancer

Circulating Inflammation Markers Associated With Risk of Lung Cancer

In a study reported in the Journal of the National Cancer Institute, Shiels et al identified 11 circulating inflammation markers significantly associated with lung cancer risk. A risk score using four of the markers distinguished risk levels among current and former smokers. Study Details This...

lung cancer

No Benefit From Adding Cetuximab to Pemetrexed in Recurrent/Progressive NSCLC After Platinum-Based Therapy

In a phase III trial reported in The Lancet Oncology, Edward S. Kim, MD, of Levine Cancer Institute, Carolinas HealthCare System, and colleagues investigated whether the addition of cetuximab (Erbitux) to pemetrexed (Alimta) improved progression-free survival in patients with recurrent or...

lung cancer

Dose-Limiting Late Toxicity Observed After Hypofractionated Dose-Escalated Radiotherapy in NSCLC

In a phase I study reported in Journal of Clinical Oncology, Donald M. Cannon, MD, of University of Wisconsin School of Medicine and Public Health and Mountain States Tumor Institute, and colleagues attempted to identify the maximum tolerated dose of dose-escalated hypofractionated radiation...

lung cancer

Improved Progression-Free but Not Overall Survival With Addition of Maintenance Erlotinib to Bevacizumab After Chemotherapy Plus Bevacizumab in NSCLC

In the phase IIIB ATLAS trial reported in the Journal of Clinical Oncology, Bruce E. Johnson, MD, of Dana-Farber Cancer Institute, and colleagues assessed the addition of maintenance erlotinib (Tarceva) to bevacizumab (Avastin) following chemotherapy plus bevacizumab in first-line treatment of ...

lung cancer
issues in oncology

Outcome Improved in MET-Positive and Worsened in MET-Negative NSCLC With Addition of Onartuzumab to Erlotinib in Phase II Trial

In patients with non–small cell lung cancer (NSCLC), increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to EGFR-targeted treatment. In a phase II study reported in the Journal of Clinical Oncology, David R. Spigel, MD, of Sarah...

lung cancer
issues in oncology

Study Identifies Prognostic DNA Methylation Signature for Stage I NSCLC

There is an absence of biomarkers to indicate which patients with stage I non–small cell lung cancer (NSCLC) would best benefit from adjuvant chemotherapy. In a study reported in the Journal of Clinical Oncology, Juan Sandoval, PhD, of the Bellvitge Biomedical Research Institute in...

lung cancer

Higher Post-Treatment FDG-PET Standardized Uptake Value Associated With Poorer Survival in Locally Advanced NSCLC

In a trial (ACRIN 6668/RTOG 0235 trial) reported in Journal of Clinical Oncology, Mitchell Machtay, MD, of Case Western Reserve University, and colleagues assessed the relationship between standardized uptake value for 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) and survival in...

breast cancer
colorectal cancer
lung cancer

Widespread Contraindicated Use of Bevacizumab in Elderly Patients

In a study reported in Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, of Columbia University, and colleagues assessed the use of bevacizumab in older patients with metastatic breast, lung, or colon cancer. They found that bevacizumab (Avastin) was contraindicated in approximately one-third ...

lung cancer
issues in oncology

Models Estimate Probability of Cancer in Pulmonary Nodules Detected on First Screening CT

In a study reported in The New England Journal of Medicine, Annette McWilliams, MD, of Vancouver General Hospital, and colleagues analyzed data from subjects undergoing low-dose computed tomography (CT) screening for lung cancer to identify factors that might predict whether lung nodules found on...

lung cancer
issues in oncology

Low-Dose CT Screening Identifies More Early Lung Cancer But Has Lower Positive Predictive Value vs Radiography

Results of the two rounds of annual incidence screening with low-dose computed tomography (CT) vs radiography in the National Lung Screening Trial (NLST) were recently reported by Denise R. Aberle, MD, of University of California at Los Angeles, and colleagues in The New England Journal of...

lung cancer

No Apparent Benefit of Adjuvant Gefitinib in Resected NSCLC in Prematurely Closed Trial

As reported in Journal of Clinical Oncology by Glenwood D. Goss, MD, of the Ottawa Hospital Cancer Center, and colleagues, the prematurely closed NCIC CTG BR19 study showed no apparent survival benefit of adjuvant gefitinib (Iressa) vs placebo in patients with completely resected non–small...

lung cancer

Chinese Study Shows Icotinib Noninferior to Gefitinib in Advanced NSCLC

In the noninferiority ICOGEN trial reported in Lancet Oncology, Yuankai Shi, MD, of the Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs. Beijing, and colleagues compared the oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor icotinib with gefitinib...

lung cancer
issues in oncology

Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial

The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...

lung cancer

Particulate Matter Air Pollution Contributes to Increased Risk of Lung Cancer in Europe

Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...

lung cancer

Docetaxel Superior to Erlotinib in Second-line Treatment of Advanced NSCLC with Wild-type EGFR

There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non–small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Marina Chiara Garassino, MD and colleagues, erlotinib was compared with standard ...

lung cancer
issues in oncology

National Lung Screening Trial Analysis Supports Risk-based Targeting of Smokers for Low-dose CT Screening

The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung cancer mortality compared with chest radiography in participants aged 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since...

lung cancer

Bevacizumab/Pemetrexed Maintenance Increases Progression-free Survival vs Bevacizumab Alone in Advanced Nonsquamous NSCLC

Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille...

lung cancer

Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC

In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...

lung cancer

Afatinib Prolongs Progression-free Survival Compared with Cisplatin plus Pemetrexed in EGFR-mutant Advanced Lung Adenocarcinoma

Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma showed...

lung cancer

Intercalated Chemotherapy plus Erlotinib Improves Survival in Asian Patients with Advanced NSCLC and Known or Unknown EGFR Mutation Status

In a phase III trial (FASTACT-2) conducted in 28 centers in seven Asian countries, Yi-Long Wu, MD, of the Guangdong Academy of Medical Sciences and colleagues found that the intercalated combination of erlotinib (Tarceva) and chemotherapy improved progression-free survival vs chemotherapy alone as...

lung cancer

Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC

In a phase III trial reported by Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients with advanced...

lung cancer

First-line Carboplatin plus Pemetrexed Improves Survival vs Pemetrexed Alone in Patients with Advanced NSCLC and Poor Performance Status

A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto...

lung cancer

Novel Selective ALK Inhibitor Demonstrates Good Activity in Advanced NSCLC

Crizotinib (Xalkori), a multitargeted receptor tyrosine kinase inhibitor, is the only agent currently available for treating ALK-rearranged non–small cell lung cancer (NSCLC). CH5424802 is a novel selective oral ALK inhibitor with activity in tumor cell lines harboring ALK alterations,...

Advertisement

Advertisement



Advertisement